Overview
No overview information available.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2014/09/11 | Phase 4 | Completed | |||
2012/09/21 | Phase 4 | UNKNOWN |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Mylan Institutional LLC | 67457-475 | INTRAVENOUS | 1 mg in 1 mL | 12/6/2018 | |
| Sun Pharmaceutical Industries, Inc. | 47335-932 | INTRAVENOUS | 1 mg in 1 mL | 10/24/2018 | |
| Sun Pharmaceutical Industries, Inc. | 47335-931 | INTRAVENOUS | 1 mg in 1 mL | 10/24/2018 | |
| Hospira, Inc. | 0409-1634 | INTRAVENOUS | 1 mg in 1 mL | 9/1/2022 | |
| HF Acquisition Co LLC, DBA HealthFirst | 51662-1547 | INTRAVENOUS | 10 mg in 1 1 | 2/22/2024 | |
| Mylan Institutional LLC | 67457-438 | INTRAVENOUS | 1 mg in 1 mL | 12/6/2018 | |
| Eugia US LLC | 55150-236 | INTRAVENOUS | 20 mg in 1 1 | 12/6/2023 | |
| Hikma Pharmaceuticals USA Inc. | 0143-9234 | INTRAVENOUS | 10 mg in 1 1 | 7/15/2019 | |
| Eugia US LLC | 55150-235 | INTRAVENOUS | 10 mg in 1 1 | 8/29/2023 | |
| Phlow Corp. | 81565-206 | INTRAVENOUS | 10 mg in 1 1 | 3/6/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| VECURE vecuronium bromide 10 mg powder for injection vial | 165350 | Medicine | A | 5/24/2011 | |
| VECURONIUM SUN vecuronium bromide 10mg powder for injection glass vial | 223371 | Medicine | A | 4/28/2015 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| VECURONIUM BROMIDE FOR INJECTION | hospira healthcare ulc | 02241524 | Powder For Solution - Intravenous | 10.00 MG / VIAL | 6/1/2000 |
| VECURONIUM BROMIDE FOR INJECTION | Pharmaceutical Partners Of Canada Inc | 02230705 | Powder For Solution - Intravenous | 10 MG / VIAL | 6/13/2000 |
| NORCURON INJ 10MG/VIAL | organon canada ltd ltee | 00687405 | Powder For Solution - Intravenous | 10 MG / VIAL | 12/31/1986 |
| VECURONIUM BROMIDE FOR INJECTION | hospira healthcare ulc | 02241525 | Powder For Solution - Intravenous | 20.00 MG / VIAL | 1/28/2000 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.